Efficacy of a combination of O-RADS, CEUS, and CA125, in identification of ovary-adnexal malignant lesions.

IF 3.6 3区医学 Q2 ONCOLOGY American journal of cancer research Pub Date : 2025-02-15 eCollection Date: 2025-01-01 DOI:10.62347/JHJJ1149

Juan Zhang, Ruili Wang, Xiaoxiao Duan, Juan Chen

{"title":"Efficacy of a combination of O-RADS, CEUS, and CA125, in identification of ovary-adnexal malignant lesions.","authors":"Juan Zhang, Ruili Wang, Xiaoxiao Duan, Juan Chen","doi":"10.62347/JHJJ1149","DOIUrl":null,"url":null,"abstract":"Objectives: To evaluate the efficacy of a combination of Ovarian-Adnexal Reporting and Data System (O-RADS), contrast-enhanced ultrasound (CEUS), and cancer antigen 125 (CA125) in identifying malignant ovarian-adnexal lesions and improving diagnostic accuracy, providing a reliable reference for the evaluation and management of ovarian-adnexal malignancies to enhance patient prognosis.Methods: The study analyzed the diagnostic performance of O-RADS alone and in combination with CEUS and CA125 for distinguishing between benign and malignant ovarian-adnexal lesions. Sensitivity, specificity, accuracy, and Kappa values were calculated to assess the efficacy of these diagnostic approaches.Results: O-RADS alone showed a diagnostic sensitivity of 88.24%, specificity of 80.77%, and accuracy of 82.61% (Kappa = 0.719). When combined with CEUS, the diagnostic accuracy and Kappa value significantly improved. The combination of O-RADS, CEUS, and CA125 further enhanced the diagnostic performance, achieving sensitivity, specificity, and accuracy of 82.35%, 98.08%, and 94.20%, respectively (Kappa = 0.804).Conclusions: The combination of O-RADS, CEUS, and CA125 significantly improves the diagnostic accuracy of ovarian-adnexal malignant lesions, providing new clinical references for the evaluation and management of ovarian-adnexal malignancies and contributing to better patient prognosis.","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 2","pages":"631-642"},"PeriodicalIF":3.6000,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897641/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/JHJJ1149","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To evaluate the efficacy of a combination of Ovarian-Adnexal Reporting and Data System (O-RADS), contrast-enhanced ultrasound (CEUS), and cancer antigen 125 (CA125) in identifying malignant ovarian-adnexal lesions and improving diagnostic accuracy, providing a reliable reference for the evaluation and management of ovarian-adnexal malignancies to enhance patient prognosis.

Methods: The study analyzed the diagnostic performance of O-RADS alone and in combination with CEUS and CA125 for distinguishing between benign and malignant ovarian-adnexal lesions. Sensitivity, specificity, accuracy, and Kappa values were calculated to assess the efficacy of these diagnostic approaches.

Results: O-RADS alone showed a diagnostic sensitivity of 88.24%, specificity of 80.77%, and accuracy of 82.61% (Kappa = 0.719). When combined with CEUS, the diagnostic accuracy and Kappa value significantly improved. The combination of O-RADS, CEUS, and CA125 further enhanced the diagnostic performance, achieving sensitivity, specificity, and accuracy of 82.35%, 98.08%, and 94.20%, respectively (Kappa = 0.804).

Conclusions: The combination of O-RADS, CEUS, and CA125 significantly improves the diagnostic accuracy of ovarian-adnexal malignant lesions, providing new clinical references for the evaluation and management of ovarian-adnexal malignancies and contributing to better patient prognosis.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

American journal of cancer research ONCOLOGY-

自引率

3.80%

发文量

263

期刊介绍： The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.